132 related articles for article (PubMed ID: 32005976)
1. A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells.
Ran R; Harrison H; Syamimi Ariffin N; Ayub R; Pegg HJ; Deng W; Mastro A; Ottewell PD; Mason SM; Blyth K; Holen I; Shore P
Oncogene; 2020 Mar; 39(12):2624-2637. PubMed ID: 32005976
[TBL] [Abstract][Full Text] [Related]
2. The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells.
Mendoza-Villanueva D; Deng W; Lopez-Camacho C; Shore P
Mol Cancer; 2010 Jun; 9():171. PubMed ID: 20591170
[TBL] [Abstract][Full Text] [Related]
3. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.
Mendoza-Villanueva D; Zeef L; Shore P
Breast Cancer Res; 2011 Oct; 13(5):R106. PubMed ID: 22032690
[TBL] [Abstract][Full Text] [Related]
4. The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER
Pegg HJ; Harrison H; Rogerson C; Shore P
Mol Cancer Res; 2019 May; 17(5):1015-1023. PubMed ID: 30655324
[TBL] [Abstract][Full Text] [Related]
5. Association of core-binding factor β with the malignant phenotype of prostate and ovarian cancer cells.
Davis JN; Rogers D; Adams L; Yong T; Jung JS; Cheng B; Fennell K; Borazanci E; Moustafa YW; Sun A; Shi R; Glass J; Mathis JM; Williams BJ; Meyers S
J Cell Physiol; 2010 Nov; 225(3):875-87. PubMed ID: 20607802
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
7. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
8. Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.
D'Amato NC; Ostrander JH; Bowie ML; Sistrunk C; Borowsky A; Cardiff RD; Bell K; Young LJ; Simin K; Bachelder RE; Delrow J; Dawson A; Yee LD; Mrózek K; Clay TM; Osada T; Seewaldt VL
PLoS One; 2012; 7(9):e45684. PubMed ID: 23049838
[TBL] [Abstract][Full Text] [Related]
9. Human-specific RNA analysis shows uncoupled epithelial-mesenchymal plasticity in circulating and disseminated tumour cells from human breast cancer xenografts.
Tachtsidis A; Le AV; Blick T; Gunasinghe D; De Sousa E; Waltham M; Dobrovic A; Thompson EW
Clin Exp Metastasis; 2019 Aug; 36(4):393-409. PubMed ID: 31190270
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer.
Brown MS; Abdollahi B; Wilkins OM; Lu H; Chakraborty P; Ognjenovic NB; Muller KE; Jolly MK; Christensen BC; Hassanpour S; Pattabiraman DR
Sci Adv; 2022 Aug; 8(31):eabj8002. PubMed ID: 35921406
[TBL] [Abstract][Full Text] [Related]
11. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
12. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
[TBL] [Abstract][Full Text] [Related]
13. MDA-9/Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 via transforming growth factor β1 to enhance epithelial-mesenchymal transition in breast cancer.
Menezes ME; Shen XN; Das SK; Emdad L; Sarkar D; Fisher PB
Oncotarget; 2016 Dec; 7(49):80175-80189. PubMed ID: 27863394
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of core binding factorβ alters sphingolipid metabolism.
Greer AH; Yong T; Fennell K; Moustafa YW; Fowler M; Galiano F; Ng SW; Berkowitz RS; Cardelli J; Meyers S; Davis JN
J Cell Physiol; 2013 Dec; 228(12):2350-64. PubMed ID: 23813439
[TBL] [Abstract][Full Text] [Related]
15. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.
Cursons J; Leuchowius KJ; Waltham M; Tomaskovic-Crook E; Foroutan M; Bracken CP; Redfern A; Crampin EJ; Street I; Davis MJ; Thompson EW
Cell Commun Signal; 2015 May; 13():26. PubMed ID: 25975820
[TBL] [Abstract][Full Text] [Related]
16. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
17. Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells.
Yang M; Ma B; Shao H; Clark AM; Wells A
BMC Cancer; 2016 Jul; 16():419. PubMed ID: 27387344
[TBL] [Abstract][Full Text] [Related]
18. Cbfβ deletion in mice recapitulates cleidocranial dysplasia and reveals multiple functions of Cbfβ required for skeletal development.
Chen W; Ma J; Zhu G; Jules J; Wu M; McConnell M; Tian F; Paulson C; Zhou X; Wang L; Li YP
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8482-7. PubMed ID: 24850862
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral bidirectional transitions between epithelial and mesenchymal cells in triple-negative breast cancer.
Yamamoto M; Sakane K; Tominaga K; Gotoh N; Niwa T; Kikuchi Y; Tada K; Goshima N; Semba K; Inoue JI
Cancer Sci; 2017 Jun; 108(6):1210-1222. PubMed ID: 28371195
[TBL] [Abstract][Full Text] [Related]
20. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Chen JH; Huang WC; Bamodu OA; Chang PM; Chao TY; Huang TH
BMC Cancer; 2019 Jun; 19(1):634. PubMed ID: 31248373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
